{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:35Z","timestamp":1792823975126,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218861","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:56:52Z","timestamp":1791907012000},"page":"218861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapy-associated myeloid niches as spatial drivers of cancer treatment resistance and targets for mechanism-matched intervention"],"prefix":"10.1016","volume":"661","author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Gang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-6112","authenticated-orcid":false,"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4960-4142","authenticated-orcid":false,"given":"Tao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218861_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib3","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-026-02924-w","article-title":"Cancer drug response and resistance: molecular mechanisms and combating strategies","volume":"11","author":"Cheng","year":"2026","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218861_bib5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib6","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101387","article-title":"Programmed cell death network in cancer drug resistance: a framework for therapeutic intervention","volume":"86","author":"Guo","year":"2026","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218861_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/2159-8290.CD-15-1283","article-title":"Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.semcancer.2022.03.012","article-title":"Chemotherapy as a regulator of extracellular matrix-cell communication: implications in therapy resistance","volume":"86","author":"Gonzalez-Molina","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218861_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.semcancer.2022.02.011","article-title":"Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells","volume":"86","author":"Berg","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218861_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.semcancer.2022.04.003","article-title":"Radiation therapy-induced remodeling of the tumor immune microenvironment","volume":"86","author":"Charpentier","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218861_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00281-022-00965-1","article-title":"Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy","volume":"45","author":"De Sanctis","year":"2023","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.canlet.2026.218861_bib14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218861_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nbt1323","article-title":"Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells","volume":"25","author":"Shojaei","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218861_bib16","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-021-23086-z","article-title":"Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer","volume":"12","author":"Shinde-Jadhav","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib17","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","article-title":"Spatial Architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer","volume":"14","author":"Enfield","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114392","article-title":"Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy","volume":"43","author":"Quek","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218861_bib19","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib22","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.21037\/tlcr-2025-244","article-title":"Single-cell and spatial transcriptomics profile the interaction of SPP1(+) macrophages and FAP(+) fibroblasts in non-small cell lung cancer","volume":"14","author":"Xiao","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-026-07978-6","article-title":"Integrated single-cell and spatial transcriptomic analysis reveals mCAF-SPP1+ macrophage-T cell crosstalk shaping immunosuppressive niches in colorectal cancer liver metastasis","volume":"24","author":"Chang","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib24","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.devcel.2023.06.006","article-title":"LYVE-1(+) macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer","volume":"58","author":"Anstee","year":"2023","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1172\/JCI40283","article-title":"Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice","volume":"120","author":"Kioi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218861_bib26","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","article-title":"Spatially segregated macrophage populations predict distinct outcomes in Colon cancer","volume":"14","author":"Matusiak","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41416-019-0725-x","article-title":"Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment","volume":"122","author":"Horikawa","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib28","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","article-title":"Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-\u03b2 activation","volume":"41","author":"Mousset","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib33","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.ccell.2024.11.005","article-title":"Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer","volume":"42","author":"Launonen","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","article-title":"The spatial Organization of cDC1 with CD8+ T cells is critical for the response to immune checkpoint inhibitors in patients with melanoma","volume":"13","author":"Gobbini","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218861_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adp3978","article-title":"Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer","volume":"10","author":"Hogg","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218861_bib36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl9330","article-title":"ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume":"7","author":"Hsieh","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218861_bib38","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1038\/s41467-024-50478-8","article-title":"A single-cell pan-cancer analysis to show the variability of tumor-infiltrating myeloid cells in immune checkpoint blockade","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib39","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib40","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218861_bib41","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","article-title":"Perivascular M2 macrophages stimulate tumor relapse after chemotherapy","volume":"75","author":"Hughes","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108194","article-title":"Metabolic control of immunity and inflammation: mitochondrial dynamics, pharmacological targets, and therapeutic opportunities","volume":"227","author":"Wang","year":"2026","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218861_bib43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib44","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","article-title":"Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion","volume":"65","author":"Zea","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib45","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218861_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib47","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218861_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126853","article-title":"Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy","volume":"4","author":"Sun","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218861_bib49","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","article-title":"Neutrophil profiling illuminates anti-tumor antigen-presenting potency","volume":"187","author":"Wu","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccell.2024.12.004","article-title":"Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10","volume":"43","author":"Lee","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib51","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218861_bib52","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nm.2172","article-title":"Lipid accumulation and dendritic cell dysfunction in cancer","volume":"16","author":"Herber","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib53","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218861_bib54","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","article-title":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","volume":"128","author":"Chen","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218861_bib55","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib57","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218861_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib59","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib60","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/0008-5472.CAN-21-3714","article-title":"Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer","volume":"82","author":"Singh","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib61","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Wilson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib62","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib63","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF\u03b1","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib64","article-title":"Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance","volume":"5","author":"Vasilevska","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib65","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib67","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/neuonc\/nos158","article-title":"Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype","volume":"14","author":"Piao","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib68","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.canlet.2026.218861_bib70","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease-directed therapy in Melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib71","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1158\/2767-9764.CRC-23-0447","article-title":"Impact of surgery-induced myeloid-derived suppressor cells and the NOX2\/ROS axis on postoperative survival in human pancreatic cancer","volume":"4","author":"Grauers Wiktorin","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib73","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/0008-5472.CAN-15-1591","article-title":"Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress","volume":"76","author":"Tohme","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib74","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218861_bib75","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2026.218861_bib76","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib77","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib78","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase I and II clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib79","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib80","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib81","article-title":"First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours","volume":"3","author":"Naing","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.canlet.2026.218861_bib82","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1158\/1078-0432.CCR-24-0499","article-title":"A phase Ib\/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"30","author":"Coveler","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib83","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218861_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106085","article-title":"Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma","volume":"11","author":"Colevas","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218861_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010006","article-title":"Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors","volume":"12","author":"Taylor","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib86","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with Hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyad022","article-title":"Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib\/II umbrella randomized Study platform","volume":"28","author":"Ko","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218861_bib88","article-title":"Injectable nanoparticle-based hydrogels enable the safe and effective deployment of immunostimulatory CD40 agonist antibodies","volume":"9","author":"Correa","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218861_bib89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1535-7163.MCT-24-0371","article-title":"Preclinical development of SGN-CD47M: Protease-Activated antibody technology enables selective tumor targeting of the innate immune checkpoint receptor CD47","volume":"24","author":"Levengood","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218861_bib90","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s43018-026-01157-8","article-title":"Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial","volume":"7","author":"Melero","year":"2026","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib91","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib92","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic Melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib93","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218861_bib94","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218861_bib95","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218861_bib96","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with Advanced\/Metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218861_bib97","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and Rituximab in non-hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib98","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib99","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41523-025-00791-2","article-title":"Spatial biomarkers of response to eribulin plus pembrolizumab in patients with metastatic triple negative breast cancer in the ENHANCE-1 trial","volume":"11","author":"Foong","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib101","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3389\/fimmu.2016.00513","article-title":"Immunodetection of NETs in paraffin-embedded tissue","volume":"7","author":"Brinkmann","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218861_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250265","article-title":"ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo","volume":"16","author":"Hayden","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218861_bib103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41592-021-01358-2","article-title":"Squidpy: a scalable framework for spatial omics analysis","volume":"19","author":"Palla","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2026.218861_bib104","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","article-title":"(68)Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial","volume":"15","author":"Shen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218861_bib105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib106","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib107","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib108","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41588-022-01041-y","article-title":"Breast tumor microenvironment structures are associated with genomic features and clinical outcome","volume":"54","author":"Danenberg","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2026.218861_bib109","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41586-024-08087-4","article-title":"Tumour evolution and microenvironment interactions in 2D and 3D space","volume":"634","author":"Mo","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218861_bib110","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41698-024-00765-w","article-title":"Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images","volume":"8","author":"Patkar","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218861_bib111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.mcb.2024.05.007","article-title":"Tumor slice culture system for ex vivo immunotherapy studies","volume":"189","author":"Arrizabalaga","year":"2024","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.canlet.2026.218861_bib112","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib113","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib114","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41378-024-00756-8","article-title":"Microdissection tools to generate organoids for modeling the tumor immune microenvironment","volume":"10","author":"Cordts","year":"2024","journal-title":"Microsyst. Nanoeng."},{"key":"10.1016\/j.canlet.2026.218861_bib115","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009494","article-title":"Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures","volume":"12","author":"Kabiljo","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib117","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41388-017-0018-x","article-title":"Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases","volume":"37","author":"Blomme","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218861_bib118","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218861_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006921","article-title":"Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment","volume":"11","author":"Chiorazzi","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218861_bib120","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.cell.2022.02.015","article-title":"Spatial CRISPR genomics identifies regulators of the tumor microenvironment","volume":"185","author":"Dhainaut","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218861_bib121","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13059-024-03404-6","article-title":"In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma","volume":"25","author":"Liu","year":"2024","journal-title":"Genome Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:21:42Z","timestamp":1792822902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":121,"alternative-id":["S0304383526006257"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218861","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-associated myeloid niches as spatial drivers of cancer treatment resistance and targets for mechanism-matched intervention","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218861"}}